Arch Capital: Attractive, Though Hurricane Season Looms
Arch Capital remains a buy despite recent underperformance, with shares offering 10% upside to my $99 target, reflecting 11x normalized earnings. Catastrophe losses, particularly from California wildfires, weighed on Q1 results, but ACGL still posted underwriting profits, highlighting its business resilience. Mortgage insurance profits are likely peaking, and increased catastrophe exposure adds near-term uncertainty, especially with hurricane season approaching.
Is Arch Capital (ACGL) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Arch Capital Group (ACGL) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Arch Capital Group (ACGL) closed at $89.78, marking a -2.78% move from the previous day.
Arch Capital Group (ACGL) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Arch Capital Group (ACGL) stood at $94.75, denoting a -1.12% change from the preceding trading day.
Arch Capital (ACGL) Up 2.5% Since Last Earnings Report: Can It Continue?
Arch Capital (ACGL) reported earnings 30 days ago. What's next for the stock?
Arch Capital Trades Above 50-Day SMA: Time to Hold ACGL Stock?
ACGL is poised to gain from new business opportunities, increased exposures, a better renewal rate environment and effective capital deployment.
Investors Heavily Search Arch Capital Group Ltd. (ACGL): Here is What You Need to Know
Arch Capital (ACGL) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Stock Picks From Seeking Alpha's April 2025 New Analysts
In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside.
Arch Capital Group Ltd. (ACGL) Q1 2025 Earnings Call Transcript
Arch Capital Group Ltd. (NASDAQ:ACGL ) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Nicolas Papadopoulo - Chief Executive Officer François Morin - Chief Financial Officer & Treasurer Conference Call Participants Michael Zaremski - BMO Capital Markets Cave Montazeri - Deutsche Bank Elyse Greenspan - Wells Fargo Andrew Kligerman - TD Cowen David Motemaden - Evercore ISI Alex Scott - Barclays Wes Carmichael - Autonomous Research Josh Shanker - Bank of America Andrew Andersen - Jefferies Meyer Shields - Keefe, Bruyette & Woods Operator Good day, ladies and gentlemen and welcome to the First Quarter 2025 Arch Capital Earnings Conference Call.
Arch Capital Q1 Earnings Surpass Estimates, Premiums Increase Y/Y
ACGL's Q1 results reflect higher premiums across its segments and improved net investment income, offset by poor underwriting income.
Compared to Estimates, Arch Capital (ACGL) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Arch Capital (ACGL) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Arch Capital Group (ACGL) Q1 Earnings Surpass Estimates
Arch Capital Group (ACGL) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $2.45 per share a year ago.
